Bepridil-d5
CAS: 64706-54-3
Ref. 3D-PCA70654
| 1mg | Discontinued | ||
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 25mg | Discontinued | ||
| 50mg | Discontinued | ||
| 100mg | Discontinued |
Product Information
- 1-Pyrrolidineethanamine, beta-((2-methylpropoxy)methyl)-N-phenyl-N-(phenylmethyl)-
- 1-Pyrrolidineethanamine, β-[(2-methylpropoxy)methyl]-N-phenyl-N-(phenylmethyl)-
- Cerm 1978
- N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline
- Org 5730
- beta-((2-Methylpropoxy)methyl)-N-phenyl-N-(phenylmethyl)-1-pyrrolidineethanamine
- dl-Bepridil
- β-[(2-Methylpropoxy)methyl]-N-phenyl-N-(phenylmethyl)-1-pyrrolidineethanamine
- Bepridil
- (±)-Bepridil
- See more synonyms
Bepridil-d5 is a potential drug target that may be used to treat infectious diseases. It has been shown to decrease intracellular Ca2+ levels in the papillary muscle of the heart, which could be useful for treating atrial arrhythmias. Bepridil-d5 also has anti-platelet effects and can be used for cardioversion. It has a structural similarity to prasugrel and can be used as an experimental model for this drug. Finally, it has been shown to decrease cardiac hypertrophy in rats with experimental heart disease. Bepridil-d5 inhibits the binding of phospholipids to platelets, which prevents platelet aggregation and reduces blood clotting. This inhibition is due to its ability to inhibit Pcsk9 activity, which is responsible for the production of prothrombotic factors such as plasminogen activator inhibitor 1 (PAI1).
